Harvard Medical School-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Harvard Medical School - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013322
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Harvard Medical School (HMS), a subsidiary of Harvard University is a medical institute that offers education, research and clinical care services. The institute offers various degree programs such as bachelor’s program, master’s program, PhD program, and continuing education. It offers programs in the areas of medical education, health sciences and technology, and medicine. HMS also conducts basic and clinical research studies. The institute offers healthcare services in the fields of anaesthesia, otology and laryngology, pathology, dermatology, pediatrics, emergency medicine, physical medicine and rehabilitation, among others. It operates through medical centers, hospital, and research institutes in Massachusetts. HMS is headquartered in Boston, Massachusetts, the US.

Harvard Medical School – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Harvard Medical School, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Harvard Medical School, Medical Devices Deals, 2011 to YTD 2017 10
Harvard Medical School, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Harvard Medical School, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
ConSynance Therapeutics Enters into Research Agreement with Harvard Medical School 13
Imcare Biotech Enters into Partnership with Harvard Medical School 14
Astellas Pharma Enters into Research Agreement with Harvard Medical School 15
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 16
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 18
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 19
Licensing Agreements 20
X-Biotix Therapeutics Enters into Licensing Agreement with Harvard Medical School 20
Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 21
Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 22
Mesoblast Enters into Licensing Agreement with Harvard Medical School 24
Columbia Labs Enters into Licensing Agreement for IVR Technology 25
GNS Healthcare Enters Into Licensing Agreement With Harvard Medical School 26
Harvard Medical School – Key Competitors 27
Harvard Medical School – Key Employees 28
Harvard Medical School – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Joint Venture 29
Recent Developments 30
Government and Public Interest 30
Oct 31, 2017: From Bench to Bedside: $4 Million Gift Supports Translational Medicine 30
Sep 15, 2017: New Study on the Placebo Effect and Antidepressants in Children and Adolescents 31
Sep 11, 2017: Scientists Construct First Predictive Model of Inflammatory Bowel Disease 32
Aug 31, 2017: Role of gut bacteria in averting Type 1 diabetes 33
Aug 21, 2017: Massachusetts Eye and Ear: Researchers identify key compounds to resolve abnormal vascular growth in age-related macular degeneration 35
Jul 19, 2017: DARPA: Building the Safe Genes Toolkit 37
Jun 27, 2017: Individualizing deep brain stimulation in patients with Parkinson’s disease 40
Apr 11, 2017: Researchers identify new target for abnormal blood vessel growth in the eyes 41
Feb 07, 2017: Cystinosis Research Foundation Grants Support Scientific Studies on Cell Function, New Treatments and the Quest for a Cure 42
Sep 19, 2016: True Health Diagnostics’ Proprietary Testing Underpins Harvard Study on Diet, Cardiac Function 44
Sep 08, 2016: New Vaccination Strategies Successfully Coach Immune System to Make Powerful HIV-Neutralizing Antibodies 45
Jun 20, 2016: Breast Cancer Cells Use Newfound Pathway to Survive Low Oxygen Levels in Tumors 47
Feb 02, 2016: New drug target for Rett syndrome 49
Product News 50
Nov 16, 2016: Next-generation biomaterial being developed to treat bleeding 50
May 19, 2016: Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment 51
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Harvard Medical School, Pharmaceuticals & Healthcare, Key Facts 2
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Harvard Medical School, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Harvard Medical School, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Harvard Medical School, Deals By Therapy Area, 2011 to YTD 2017 9
Harvard Medical School, Medical Devices Deals, 2011 to YTD 2017 10
Harvard Medical School, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
ConSynance Therapeutics Enters into Research Agreement with Harvard Medical School 13
Imcare Biotech Enters into Partnership with Harvard Medical School 14
Astellas Pharma Enters into Research Agreement with Harvard Medical School 15
Genocea Biosciences Enters Into Research Agreement With Dana-Farber Cancer Institute And Harvard Medical School 16
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 18
Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 19
X-Biotix Therapeutics Enters into Licensing Agreement with Harvard Medical School 20
Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 21
Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 22
Mesoblast Enters into Licensing Agreement with Harvard Medical School 24
Columbia Labs Enters into Licensing Agreement for IVR Technology 25
GNS Healthcare Enters Into Licensing Agreement With Harvard Medical School 26
Harvard Medical School, Key Competitors 27
Harvard Medical School, Key Employees 28
Harvard Medical School, Subsidiaries 29
Harvard Medical School, Joint Venture 29

★海外企業調査レポート[Harvard Medical School-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Laredo Petroleum Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Laredo Petroleum Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Laredo Petroleum Inc (Laredo), formerly known as Laredo Petroleum Holdings, Inc., is an independent energy company that acquires assets, and explores for, develops and produces oil and natural g …
  • Meiji Holdings Co, Ltd.:企業の戦略・SWOT・財務情報
    Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Reliance Infrastructure Ltd.:企業の戦略・SWOT・財務情報
    Reliance Infrastructure Ltd. - Strategy, SWOT and Corporate Finance Report Summary Reliance Infrastructure Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Electrica SA (EL):電力:M&Aディール及び事業提携情報
    Summary Electrica SA (Electrica) is a power utility that distributes and supplies electricity. Its services include electricity supply, distribution, and trading, and power distribution networks operations and management, and design and consultation for aerial and subterranean power networks. It als …
  • Antitope Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Antitope Ltd (Antitope), a subsidiary of Abzena Plc is a life science company that research and develops technologies for various therapeutic areas. The company’s iTope technology is used to identify peptides; and T Cell Epitope Database is used for screening amino acid sequences from antibo …
  • Spinal Elements Inc-医療機器分野:企業M&A・提携分析
    Summary Spinal Elements Inc (Spinal Elements), formerly Quantum Orthopedics Inc, a subsidiary of Amendia Inc, is a medical device company that manufactures spinal implants and instruments. The company provides products such as cervical interbody system, cervical implant system, anterior cervical pla …
  • Fresenius Kabi USA LLC:企業の戦略的SWOT分析
    Fresenius Kabi USA LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Bio-Rad Laboratories Inc (BIO):医療機器:M&Aディール及び事業提携情報
    Summary Bio-Rad Laboratories Inc (Bio-Rad) develops, manufactures and markets a range of products and systems for the life science research, healthcare, analytical chemistry and other markets. The company’s major products include reagents, apparatus, laboratory instruments, test systems, informatics …
  • Hisamitsu Pharmaceutical Co Inc (4530):製薬・医療:M&Aディール及び事業提携情報
    Summary Hisamitsu Pharmaceutical Co Inc (Hisamitsu Pharmaceutical) is a pharmaceutical company that provides pain management products. The company manufactures and sells pain relieving products, dermatological products, and quasi drugs, among others. Hisamitsu Pharmaceutical provides its products in …
  • Hologic, Inc.:企業の戦略・SWOT・財務情報
    Hologic, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hologic, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Fresenius Kabi USA LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Fresenius Kabi USA LLC (Fresenius Kabi), a subsidiary of Fresenius Kabi AG, is a pharmaceutical and medical device company which provides lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. It provides products and services to critically and chronically il …
  • PetroChina Co Ltd (857):企業の財務・戦略的SWOT分析
    PetroChina Co Ltd (857) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • FEMSA Comercio, S.A. de C.V.:企業の戦略・SWOT・財務情報
    FEMSA Comercio, S.A. de C.V. - Strategy, SWOT and Corporate Finance Report Summary FEMSA Comercio, S.A. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • DHL Parcel UK Ltd:企業の戦略的SWOT分析
    DHL Parcel UK Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Houston American Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    Houston American Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary Houston American Energy Corp (Houston American Energy) is an oil and gas company that provides exploration and development services. The company concentrates on development, exploration, …
  • 3SBio Inc (1530):製薬・医療:M&Aディール及び事業提携情報
    Summary 3SBio Inc (3SBio) is a biotechnology companies that carries out the research, development, manufacturing and marketing of biopharmaceutical products. It develops recombinant, or genetically engineered, protein-based products and other pharmaceutical product candidates to address large market …
  • The Emirates Group:企業の戦略・SWOT・財務情報
    The Emirates Group - Strategy, SWOT and Corporate Finance Report Summary The Emirates Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • REVA Medical Inc (RVA):医療機器:M&Aディール及び事業提携情報
    Summary REVA Medical Inc (REVA) is a medical device company that offers bioresorbable polymer technologies for vascular applications. The company offers solutions for patient health restoration through the application of biomaterials in the development and sale of implantable medical devices. It off …
  • EXOR SpA:戦略・SWOT・企業財務分析
    EXOR SpA - Strategy, SWOT and Corporate Finance Report Summary EXOR SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Meezan Bank Ltd:企業の戦略・SWOT・財務情報
    Meezan Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Meezan Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆